Curia and Replicate Bioscience enter into a strategic collaboration to create a self-replicating RNA development platform

Curia and Replicate Bioscience enter into a strategic collaboration to create a self-replicating RNA development platform

June 21, 2022 – Curia and Replicate Bioscience, a company pioneering the use of self-replicating RNA (srRNA) to prevent drug resistance in cancer and treat autoimmune, inflammatory and other diseases, announced today that they have joined forces to develop a robust development platform for Replicate’s srRNA therapeutics will work together. The strategic collaboration brings together two industry leaders in RNA therapeutics.

As part of the collaboration, Curia’s experienced process development team will support GMP production of Replicate Bioscience’s srRNA vectors at scales of up to eight liters (8L) for use in Phase 1 through pivotal clinical trials. Curia’s global mRNA development and manufacturing facility is ISO 13485 accredited and located near Boston, Massachusetts. This facility also supports innovators involved in the development and manufacture of vaccines and other phase 2 and 3 mRNA therapies, including GMP assays. Additional Curia facilities support the production of srRNA on a commercial scale.

“Replica’s approach to srRNA is unique in that we create our own viral synthetic vectors to tailor srRNAs to deliver specific proteins,” said Andrew Geall, Ph.D., Replicate’s co-founder and chief development officer , who previously founded srRNA-CMC frameworks for companies such as Novartis, Synthetic Genomics and Precision Nanosystems. “This adaptation has important therapeutic advantages – versatility of use, lower dosage and longer duration of therapeutic effect compared to other RNA modalities – but requires dedicated processes to solve the challenges of making longer RNAs.” Curia’s unparalleled expertise in process development and end-to-end integration of longer RNAs makes them a perfect partner for us as we transition from research to clinical development and production of our srRNA for patient studies.”

“The production of these longer mRNAs is more technically challenging than non-replicating mRNAs, and to date we have had success with mRNAs up to 16,000 bases,” said Norman Garceau, Ph.D., Vice President, Global R&D Technology, Curia. “Curia’s platform offers versatility and optimized manufacturing times that can handle such complex molecules. Our collaboration with Replicate Bioscience enables us to develop completely new methods to produce longer RNAs. We built our platform from the ground up, leveraging our combined expertise in biologics and chemistry to develop end-to-end solutions covering mRNA synthesis, lipid synthesis, formulation and filling of liquid nanoparticles. We are proud to use our skills and expertise to support the Replicate Bioscience team and their innovative approach.”

learn more

Leave a Comment

Your email address will not be published.